SCHEMBL8937469

SCHEMBL8937469

CCCOc1cccc(/C(=C\C(=O)O)c2ccccc2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.67
NR1H4 Q96RI1 1/20 0.53
KAT6A Q92794 4/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
LMNA P02545 2/20 0.53
NPC1 O15118 1/20 0.53
ALDH1A1 P00352 1/20 0.53
RAB9A P51151 1/20 0.53
MAPT P10636 2/20 0.51
TP53 P04637 1/20 0.51
MAPK1 P28482 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
ADRB2 P07550 1/20 0.48
ADRB1 P08588 1/20 0.48
ADRB3 P13945 1/20 0.48
PLA2G4B P0C869 1/20 0.48
SMPD1 P17405 3/20 0.48
MEN1 O00255 1/20 0.47
TAAR1 Q96RJ0 1/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937473 1.00 KMT2A (0.67) KMT2ANR1H4KAT6ASMN1; SMN2LMNA
SCHEMBL8937464 1.00 KMT2A (0.67) KMT2ANR1H4KAT6ASMN1; SMN2LMNA
SCHEMBL13236855 0.92 KMT2A (0.59) KMT2ANR1H4KAT6APLA2G4BSMPD1
SCHEMBL8937303 0.90 KMT2A (0.60) KMT2ANR1H4KAT6ASMN1; SMN2LMNA
SCHEMBL8937434 0.90 KMT2A (0.60) KMT2ANR1H4KAT6ASMN1; SMN2LMNA
SCHEMBL8937306 0.90 KMT2A (0.60) KMT2ANR1H4KAT6ASMN1; SMN2LMNA
SCHEMBL8937565 0.83 MAPT (0.60) KMT2ANR1H4SMN1; SMN2LMNANPC1
SCHEMBL8937571 0.83 MAPT (0.60) KMT2ANR1H4SMN1; SMN2LMNANPC1
SCHEMBL8937615 0.83 MAPT (0.60) KMT2ANR1H4SMN1; SMN2LMNANPC1
SCHEMBL11696519 0.81 KMT2A (0.77) KMT2ANR1H4KAT6ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed